TMC-310911Other Names: ASC-09 Drug Class: Protease Inhibitors Molecular Formula: C38 H53 N5 O7 S2 Registry Number: 1000287-05-7 (CAS) Chemical Name: [(4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(1S,2R)-1-benzyl-3-[[2-[(1-cyclopentyl-4-piperidyl)amino]-1,3-benzothiazol-6-yl]sulfonyl-isobutyl-amino]-2-hydroxy-propyl]carbamate Organization: Janssen Research and Development, LLC Phase of Development: TMC-310911 is in Phase IIa development for HIV treatment.
(Compound details obtained from ChemIDplus Advanced,1 NIAID Therapeutics Database,2 and Journal of Acquired Immune Deficiency Syndromes article3)
What is TMC-310911?
TMC-310911 is anthat is being studied to treat HIV .
TMC-310911 belongs to a group of HIV drugs calledinhibitors (PIs).2 PIs block an HIV , a type of , called protease.
, TMC-310911 has shown activity against strains of HIV that are no longer affected by other PIs.4
Which clinical trials are studying TMC-310911?
Study Name: NCT00838162
Status: This study has been completed.
Purpose: The purpose of this study was to evaluate the safety and effectiveness of TMC-310911 when given with a low of the HIV medicine ritonavir.3,5
For more details on this study, see the Health Professional version of this drug summary.
What side effects might TMC-310911 cause?
One goal of HIV research is to identify new drugs that have fewer side effects. The most common side effects in the NCT00838162 study, which occurred in at least 10% of participants, were fatigue and nausea. Most side effects were mild to moderate in severity. Side effects related to the system (such as nausea, diarrhea, and frequent bowel movements) occurred in more than 25% of the study participants. One participant had a temporary increase in enzyme levels that may have been caused by TMC-310911.3
Because TMC-310911 is still being studied, information on possible side effects of the drug is not complete. As testing of TMC-310911 continues, additional information on possible side effects will be gathered.
Where can I get more information about clinical trials studying TMC-310911?
More information about TMC-310911-related research studies is available from ClinicalTrials.gov.
- United States National Library of Medicine. ChemIDplus advanced: TMC-310911. https://chem.nlm.nih.gov/chemidplus/rn/1000287-05-7. Accessed January 3, 2019.
- National Institute of Allergy and Infectious Diseases (NIAID). NIAID ChemDB, HIV Drugs in Development. https://chemdb.niaid.nih.gov/DrugDevelopmentHIV.aspx. Accessed January 3, 2019.
- Stellbrink H-J, Arastéh K, Schürmann D, et al. Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1–infected patients. J Acquir Immune Defic Syndr. 2014;65(3):283-289.
- Dierynck I, Van Marck H, Van Ginderen M, et al. TMC310911, a novel human immunodeficiency virus Type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrob Agents Chemother. 2011;55(12):5723-5731.
- Tibotec Pharmaceuticals, Ireland. A Phase IIa, open-label, randomized trial in treatment-naive HIV-1-infected subjects to determine the antiviral activity of 14 Days of monotherapy with 4 different dose regimens of TMC310911 coadministered with ritonavir. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 5, 2009. NLM Identifier: NCT00838162. https://clinicaltrials.gov/ct2/show/NCT00838162. Accessed January 3, 2019.
Last Reviewed: January 17, 2019
- Patient Version HTML